Posted by Michael Wonder on 01 Jun 2023
BMS Korea wins insurance coverage for myelofibrosis drug Inrebic
1 June 2023 - BMS Korea has announced that Inrebic (fedratinib), its myelofibrosis drug, will now be covered by the national health insurance system in Korea starting from 1 June.
Inrebic is a second-line treatment for myelofibrosis that selectively inhibits the JAK2 gene mutation, and can help improve the splenomegaly and associated symptoms of primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after essential thrombocythemia in adult patients treated with ruxolitinib.
Accordingly, insurance coverage is available for the treatment of the aforementioned cases based on the clinical improvement response of the International Working Group-European LeukemiaNet (IWG-ELN) guidelines.
